TOT BIOPHARM raises US$102 million in Series B Financing RoundTOT BIOPHARM's high-end oncology drug technology platform garners great attention SUZHOU, China, August 8, 2018-- TOT BIOPHARM Company Limited ("TOT BIOPHARM"), headquartered in Suzhou Industrial Park, China, today announced the completion of a Series B financing round, raising US$102 million in capital. The financing round was supported by China Universal (Cayman) GP Limited and several renowned domestic and foreign investors, as well as investors who had participated in earlier rounds, including Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.